肝细胞癌立体定向体部放射治疗的局部肿瘤控制与患者结局:iRECIST可能替代传统标准
回顾性纳入41例肝细胞癌患者共51个病灶(平均大小3.1 cm),评估SBRT后iRECIST与传统标准对局部肿瘤控制和生存的预测价值。iRECIST的局部肿瘤控制率为94.1%(48/51),显著高于WHO和EASL标准;iRECIST判定局部肿瘤控制者的1年生存率为86.4%,高于其他标准但未达统计学显著。结论认为iRECIST可能为HCC SBRT后疗效提供更稳健的解读。
要点
- SBRT后iRECIST的局部肿瘤控制率为94.1%(48/51),高于RECIST 1.1的88.2%。
- iRECIST的局部肿瘤控制率显著高于WHO(p=0.0010)和EASL(p=0.0225)标准。
- iRECIST判定局部肿瘤控制者1年生存率86.4%,高于其他标准但未达统计学显著。
核心结论
- iRECIST可能为HCC患者SBRT后的疗效反应提供更稳健的解读,相较传统标准可改善对局部肿瘤控制和1年生存率的预测。
研究设计与样本
- 回顾性纳入41例肝细胞癌患者共51个病灶(平均大小3.1 cm,平均年龄67岁),SBRT前及SBRT后至少一次行CT或MRI检查。
诊断标准与关键数值
- 局部肿瘤控制率按iRECIST为94.1%(48/51),RECIST 1.1为88.2%(45/51),WHO标准为72.5%(37/51),mRECIST为80.4%(41/51),EASL标准为72.5%(37/51)。
临床应用与阅片要点
- 作者认为iRECIST可能为HCC患者SBRT后的疗效反应提供更稳健的解读,并改善对局部肿瘤控制和1年生存率的预测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE. The purpose of this study was to investigate whether, compared with traditional criteria, the modified Response Evaluation Criteria in Solid Tumors version 1.1 for immune-based therapeutics (iRECIST) improves prediction of local tumor control and survival in patients with hepatocellular carcinoma (HCC) treated with stereotactic body radiotherapy (SBRT). MATERIALS AND METHODS. Fifty-one HCC lesions (mean size, 3.1 cm) treated with SBRT in 41 patients (mean age, 67 years) were retrospectively included. Each patient underwent CT or MRI before SBRT and at least once after SBRT. Best overall response was categorized using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), iRECIST, World Health Organization (WHO) criteria, modified Response Evaluation Criteria in Solid Tumors (mRECIST), and European Association for the Study of the Liver (EASL) criteria. Lesions were then classified as local tumor control (i.e., stable disease, partial response, or complete response) or local treatment failure (i.e., progressive disease) by each tumor response criteria. Proportions of local tumor control were compared using the McNemar exact test. The 1-year overall survival was estimated using the Kaplan-Meier method. RESULTS. The median follow-up after SBRT was 21.0 months. The local tumor control rate was 94.1% (48/51) by iRECIST, 88.2% (45/51) by RECIST 1.1, 72.5% (37/51) by WHO criteria, 80.4% (41/51) by mRECIST, and 72.5% (37/51) by EASL criteria. The local tumor control rate was significantly higher according to iRECIST compared with WHO (p = 0.0010) and EASL (p = 0.0225) criteria. The 1-year survival rate for patients with local tumor control according to iRECIST (86.4%) was higher (although not statistically significant) compared with the 1-year survival rate for patients with local tumor control according to the other response criteria. CONCLUSION. iRECIST may provide more robust interpretation of HCC response after SBRT, yielding improved prediction of local tumor control and 1-year survival rates compared with traditional criteria.
引用
- Vernuccio F, Godfrey D, Meyer M, et al. Local Tumor Control and Patient Outcome Using Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: iRECIST as a Potential Substitute for Traditional Criteria. AJR Am J Roentgenol. 2019. PMID: 31613663. doi:10.2214/AJR.18.20842
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。